Myriad Genetics, Inc. — Earnings Quality Grade F
MYGN · Healthcare
Major red flags
Screening Summary
Management Signals
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
DSO 51 days, change -2 days YoY
AR growth -4.9% vs revenue growth -1.6%
Revenue -1.6%, CFFO 120.7%. Cash follows revenue
Expense Quality
Inventory 11.3% vs COGS -1.7%. Normal
CapEx growth -7.7% vs revenue -1.6%. Normal
SG&A/Gross Profit = 93.2%, exceeds 70%
Gross margin 69.9%, change +0.0pp. Stable
Cash Flow Quality
CFFO < Net Income for 3 consecutive years
Small-cap context: Small-cap CFFO/NI often diverges from working-capital swings, not necessarily manipulation.
FCF is negative ($-0.0B)
Accruals ratio = -52.0%. Low accruals
Cash $0.1B covers 71% of debt $0.2B
Balance Sheet Health
Goodwill+Intangibles $0.2B = 56% of equity. Over 50%
Interest coverage = -6.5x (<2x). Financial stress
Other assets -34.1% vs revenue -1.6%. Normal
No write-off data
Acquisition Risk
FCF after acquisitions negative for 3 years
Small-cap context: A single acquisition on a small balance sheet can trip serial-acquirer logic.
Goodwill+Intangibles change -63% YoY. Normal
Manipulation Score
M-Score = -5.40 (< -2.22). Unlikely manipulator
Portfolio monitoring
Monitor MYGN continuously
The full checks and model details are free to read. Use Watchlist to track your holdings; Pro adds automatic quarterly rescoring, risk-event email alerts, scans up to 50 tickers, and export workflows.
Beneish M-Score
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25